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Ensa controls S-phase length by modulating Treslin
levels
Sophie Charrasse1, Aicha Gharbi-Ayachi1, Andrew Burgess 2,3, Jorge Vera1, Khaled Hached1, Peggy Raynaud1,
Etienne Schwob4, Thierry Lorca1 & Anna Castro1
The Greatwall/Ensa/PP2A-B55 pathway is essential for controlling mitotic substrate phos-
phorylation and mitotic entry. Here, we investigate the effect of the knockdown of the Gwl
substrate, Ensa, in human cells. Unexpectedly, Ensa knockdown promotes a dramatic
extension of S phase associated with a lowered density of replication forks. Notably, Ensa
depletion results in a decrease of Treslin levels, a pivotal protein for the firing of replication
origins. Accordingly, the extended S phase in Ensa-depleted cells is completely rescued by
the overexpression of Treslin. Our data herein reveal a new mechanism by which normal cells
regulate S-phase duration by controlling the ubiquitin-proteasome degradation of Treslin in a
Gwl/Ensa-dependent pathway.
DOI: 10.1038/s41467-017-00339-4 OPEN
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A precise spatiotemporal regulation of DNA replication iscrucial for the maintenance of genomic integrity. DNAmust be replicated once and only once during each cell
cycle. Additional rounds of replication within a given cell cycle
result in gene amplification, polyploidy and/or other kinds of
genomic instability. Under-replication or late DNA replication
can also cause genome instability, as for common fragile sites for
example. Correct DNA duplication involves the strictly ordered
assembly of various protein complexes onto thousands of geno-
mic sites that will be destined to serve as replication origins1, 2.
The origin recognition complex (ORC) first binds the replication
origins. This complex promotes the binding of Cdc6 and Cdt1,
two proteins that will subsequently facilitate the binding of the
MCM proteins to form the pre-replication complex (pre-RC).
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Pre-RC formation process starts in late M phase and continues
during early G1 when cyclin-dependent kinase (Cdk) activity is
low. The subsequent initiation of DNA replication involves the
activation of the MCM complex via the recruitment of the
replication proteins Cdc45 and GINS that occurs at G1/S tran-
sition when interphase Cdk activity increases3. It is known that
Cdks globally orchestrate transition at origin-bound complexes
regulating licensing and initiation events to ensure that each
origin is fired only once per cell cycle. During S, G2 and M phases
origin licensing is prevented by high levels of Cdk activity that
phosphorylate and inactivate multiple pre-RC components. One
of these components, Cdt1, is inactivated during S phase by SCF-
Skp2-dependent degradation as a consequence of Cdk-dependent
phosphorylation4, 5. Another replication factor, Cdc6, is also
phosphorylated by Cdk during DNA replication and this phos-
phorylation downregulates its licensing activity by promoting
nuclear exclusion6–8. Finally, ORC1 phosphorylation by Cdk
during S phase reduces its chromatin affinity9 and permits its
export to the cytoplasm preventing the formation of new pre-
RC10. Unlike its negative effect on origin licensing, Cdk activity
positively regulates origin firing at G1/S transition. In humans,
Cdk phosphorylates Treslin, the orthologue of yeast Sld3, pro-
moting its binding to TopBP1, the subsequent recruitment of
Cdc45 to the pre-RC and the activation of the MCM
helicase11–14. Sld3 has also been shown to bind MCM2-7 helicase
and Dbf4-Cdc7 kinase. This binding stimulates DDK-dependent
phosphorylation of MCM2 decreasing the affinity of this protein
for MCM5 and probably facilitating in this way helicase ring
opening15, 16. Recent data suggest that Cdk activity, through the
phosphorylation of Treslin, controls S-phase length by regulating
fork number14.
Cdk activity plays a pivotal role not only in S phase but also in
mitosis. Mitosis in most animal cells is promoted by the activa-
tion of cyclin B-Cdk1. Once activated, this kinase can phos-
phorylate a large number of substrates, thereby promoting major
cellular reorganisation such as nuclear envelope breakdown,
chromatin condensation and spindle formation. However, the
phosphorylation state of cyclin B-Cdk1 substrates during mitosis
is not exclusively dependent on the activity of this kinase but also
on the activity of the phosphatase responsible of its depho-
sphorylation. Extensive work during the last 4 years has shown
that mitotic entry is the result of the activation of the cyclin B-
Cdk1 kinase and the inhibition of the phosphatase PP2A-B55.
We, and others demonstrated that the activation of the Greatwall
(Gwl) kinase at the G2/M transition via the phosphorylation of its
substrates Arpp19 and Ensa, promotes the inactivation of PP2A-
B55, the phosphatase responsible of the dephosphorylation of
cyclin B-Cdk1 substrates17–20. This inactivation results in the
stable phosphorylation of these substrates and correct entry and
progression through mitosis. Here, we investigated the effect of
the knockdown (KD) of the Gwl substrate, Ensa, in human cells.
Our data demonstrate that Gwl/Ensa/PP2A-B55 axis regulates S
phase by controlling the Cullin-dependent degradation of the
pivotal replication factor Treslin.
Results
Ensa KD promotes a delay of cells in S phase. Ensa has been
firstly identified as one of the substrates of Gwl whose phos-
phorylation promotes the inhibition of PP2A-B55 and sub-
sequent mitotic entry in Xenopus egg extracts. Little is known
about the role of this protein in human cells. We sought to
understand whether the role of this protein is conserved in
humans. Toward this end, we carried out a small interfering RNA
(siRNA) KD in HeLa cells. We used two siRNAs directed against
two different sequences of the messenger RNA (mRNA) of this
gene (siEnsa1 and siEnsa2). Both siRNAs efficiently depleted
endogenous Ensa, with western blot analysis clearly showing the
loss of a band corresponding to the molecular weight of Ensa in
the targeting siRNAs, but not in the scramble siRNA (siSC)
transfections (Fig. 1a). siEnsa1 transfection also caused a 90%
decrease of the levels of an ectopically overexpressed green
fluorescent protein (GFP)-hEnsa (Fig. 1b, c). Fluorescence-
activated cell scanning (FACS) analysis of asynchronous HeLa
cells 48 h after transfection with the two Ensa siRNAs revealed,
unexpectedly, a dramatic accumulation in S phase, along with the
apparition of a small subG1 population (Fig. 1d). A similar
phenotype, although less striking, was observed when U2OS cells
were knocked down of Ensa (Fig. 1e, f). This accumulation of cells
in S phase was confirmed by bivariate FACS and indirect
immunofluorescence after a brief BrdU incorporation and by
EdU staining and immunofluorescence (Fig. 1g–i, respectively).
To further characterise this phenotype, we synchronised the
cells in S phase by thymidine treatment for 24 h, 1 day after
siRNA transfection. Since both Ensa siRNAs behaved similarly,
we mostly used siEnsa1 for the rest of the study. Synchronised
HeLa and U2OS cells were then analysed by FACS at different
times after release from the thymidine arrest. Ensa knocked down
cells remained in S phase as long as 10 h (HeLa) or 14 h (U2OS)
after release, much longer than control cells, which already passed
through mitosis and entered the next G1 by that time (Fig. 2a, b).
To determine S-phase length, we performed a bromodeoxyur-
idine (BrdU)/5-ethyl-2′-deoxyuridine (EdU) double labelling in
asynchronous HeLa cells treated with siSC or siEnsa1 RNA
(Fig. 2c). Cells were pulse-labelled for 30 min with EdU, then
washed, maintained in the medium before being pulsed again
Fig. 1 Ensa KD strongly delays cells in S phase. a HeLa cells were treated with scramble siRNA (siSC) or Ensa siRNA#1 (siEnsa1) or #2 (siEnsa2) for 48 h.
a Ensa levels and, as a loading control, β-tubulin(βTub) were checked in these cells by immunoblot. b Ensa-GFP was overexpressed in control cells
(parental or transfected with siSC) and in cells knocked down of Ensa with siEnsa1 and GFP fluorescence intensity was analysed by FACS. c GFP levels in b
were quantified by densitometry using ImageJ and represented as % of fluorescence towards GFP levels on parental cells. d HeLa cells, treated with SC
siRNA (siSC) or siEnsa1 or siEnsa2, were stained with propidium iodide and analysed by FACS. DNA content (x-axis, propidium iodide) is represented
towards the relative number of cells (y-axis, counts). Coloured panel represents a merge of all conditions. The quantification of % of total cells in SubG1, G1,
S and G2/M phases in each cell type is represented as a bar histogram. e As for d except that U2OS instead of HeLa cells where used. f Endogenous Ensa
levels in U2OS treated with siSC and siEnsa1 were analysed by western blot and shown. g Cells treated with control SC siRNA (left) or siEnsa1 (right) were
incubated in the presence of BrdU for 30min at 48 h post transfection and analysed by bivariate FACS. Intensity of BrdU incorporation and DNA content
was analysed by using anti-BrdU antibodies and 7-AAD staining, respectively. Boxed area indicates the percentage of cells in S phase (incorporating BrdU),
and in G1 (2n DNA content non incorporating BrdU) or G2/M (4n DNA content) phases (Flow Jo analysis). h Cells treated with siSC or siEnsa1 or siEnsa2
were incubated in presence of EdU for 60min at 48 h post transfection and incorporated EdU was subsequently detected by Click-iT reagent. Scale bar, 5
μm. i The percentage of EdU-positive cells towards the total cell number (determined by differential interferene contrast microscopy (DIC)) in each
condition was represented as a bar graph of the mean value ± standard deviation
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with BrdU (30 min) at 2, 4, 6, 8 or 10 h after EdU and finally fixed
for immunofluorescence (Fig. 2d). S-phase length was calculated
by measuring the percentage of BrdU/EdU-double-positive cells
at each time point (Fig. 2e). This percentage decreased gradually
in siSC cells reaching a minimum at 10 h after the first pulse,
which suggests that S phase lasts around >10 h in these cells. In
contrast, the percentage of double-positive siEnsa cells remained
high throughout the experiment, indicating that S phase in these
cells was much longer than 10 h.
To further examine the specificity of the phenotype induced by
Ensa depletion, we investigated the effect of increasing doses of
siEnsa on S–G2 length. HeLa cells were transfected with the
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indicated doses of siRNA and synchronised by thymidine block.
S-phase synchronised cells were then released and followed by
time-lapse microscopy. The time between thymidine release and
cell rounding (mitotic entry) was calculated as previously
described18. Similar to FACS, siSC cells progressed through S
phase and began entering mitosis on average 8.5 h after release.
Increasing doses (12.5, 25 and 50 nM) of siEnsa showed a
corresponding increase in S–G2 length with median values of 15,
16.5 and 17.5 h, respectively (Fig. 2f). Finally, to investigate the
specificity of our siEnsa, we generated HeLa cells that stably
expressed a siRNA-resistant transgene of human Ensa (R-Ensa).
Overexpression of R-Ensa had no noticeable effect on S-phase
progression (Supplementary Fig. 1). HeLa and R-Ensa-HeLa cells
were transfected with siRNA (scramble or siEnsa) for 24 h, then
later synchronised (Fig. 2h) or not (Fig. 2g) for 21 h with
thymidine and analysed by FACS at 9 h after release. As expected,
control HeLa cells treated with siEnsa displayed a dramatic delay
in S phase in both asynchronous cells and in synchronic cells 9 h
after release. In contrast, at this time, the majority of scramble
siRNA-treated cells had completed S phase and were undergoing
mitosis. Importantly, stable overexpression of R-Ensa in HeLa
cells rescued the S-phase delay induced by the KD of Ensa. These
data indicate that our siRNAs specifically induce Ensa KD and
that this depletion dramatically extends S phase.
Ensa KD extends S phase by decreasing fork number. The
increase of S-phase length induced by Ensa KD could be the result
of a decrease of fork rate or fork number. To discriminate
between these hypotheses, we used DNA combing. Newly repli-
cated DNA was labelled by sequentially treating cells for 15 min
with two different thymidine analogues: iododeoxyuridine (IdU),
then chlorodeoxyurindine (CldU). Tracts of ongoing DNA
replication were identified as adjacent IdU–CldU signals on
individual DNA fibres (Fig. 3a, b). Mean fork rate was calculated
by dividing tract length by pulse duration on each in an ongoing
replication tract, whereas fork density was calculated by dividing
the total number of bicolour forks by the total length of DNA
fibres analysed after normalisation for the fraction of S-phase
cells. No differences in fork rate was observed between siSC and
siEnsa-treated cells (Fig. 3c), however, fork density significantly
decreased in Ensa knocked down cells (median values: 1.50 forks
per Mb in siSC vs 0.92 forks per Mb in siEnsa cells; Fig. 3d). This
strongly suggests that increased DNA replication time in the
Ensa-depleted cells was the result of a decreased number of active
replication origins.
The Gwl/Ensa pathway is essential for mitotic entry and
controls mitotic progression. During late mitosis and early G1,
pre-RC formation occurs as a sequential assembly of the licensing
factors Cdc6 and Cdt1 onto ORC-bound chromatin, which then
recruit the MCM2-7 complex2, 21. It is possible that defects in
mitotic progression due to Ensa depletion could perturb pre-RC
formation and licensing during late M/early G1 phase resulting in
a decreased number of replication origins and subsequent
decreased fork number. In order to test this hypothesis, we
designed an experiment in which synchronised cells were allowed
to traverse mitosis and G1, thus making preRCs, before being
transfected with siEnsa (4 h after nocodazole shakeoff) and 1 h
later blocked in S phase by thymidine addition for 18 h to allow
Ensa depletion (Fig. 3e). In this scheme, Ensa is depleted at a
stage after origin licensing, thus any S-phase delay after release
would indicate a role of Ensa in origin firing, not licensing. This
was indeed the case, with siEnsa cells presenting the same slow S-
phase progression as asynchronous siEnsa-transfected cells
(Fig. 3f). To deeper analyse whether Ensa KD could affect origin
licensing, we checked the levels of MCM proteins in the
chromatin fraction of siSC and siEnsa HeLa-and U2OS-treated
cells (Fig. 3g, h). Cytosolic (S2) and nuclear soluble (S3) fractions
as well as chromatin fraction (P3) were purified from nuclei of
these cells as described in Methods section and used for western
blot analysis. As expected from the data above, the levels of the
different chromatin-bound MCM did not significantly change in
Ensa KD cells confirming that the depletion of this protein is not
affecting origin licensing. We conclude that the decrease of fork
density in Ensa-depleted cells is unlikely to be due to a defect in
pre-RC formation, but rather in the firing of origins.
Ensa KD does not alter spatiotemporal replication pattern. Our
data show that Ensa KD causes an extension of S phase. To get
more insight into this phenotype, we analysed the spatiotemporal
pattern of replication foci in Ensa-depleted HeLa cells stably
expressing a proliferating cell nuclear antigen (PCNA)-targeting
chromobody fused to GFP, allowing the visualisation of endo-
genous PCNA foci22. After siRNA transfection, cells were imaged
for 72 h by time-lapse microscopy. The direct visualisation of
replication factories in vivo confirmed that S-phase length was
dramatically increased in Ensa knocked down cells with a mean
time corresponding to 7 h in scramble and 11 h in siEnsa-treated
cells (Fig. 4a, Supplementary Movies 1–6).
We could distinguish early, mid and late replication factories in
both scramble and siEnsa-treated cells following previous
described nomenclature as shown in Fig. 4b23. However,
interestingly, although we could not quantify differences in
intensity or size due to variable basal GFP intensities and different
replication factory shapes, we noticed clear alterations on the
localisation and the size of mid-replication factories between
scramble and siEnsa-treated cells. Specifically, in scramble-treated
cells, mid-replication factories were small, creating a continuous
and complete circumference around nucleoli. In contrast, in
Fig. 2 Ensa KD increases S-phase length. a HeLa cells treated with SC or Ensa siRNA were blocked in G1/S by thymidine and released in fresh medium.
Samples were taken at 4, 6, 8 and 10 h after release and processed by FACS to follow S-phase progression. b As for a except that U2OS cells were used
and released at 4, 9, 14 and 17 h. c Scheme representing the experiment in which HeLa cells were treated with SC or Ensa siRNA for 48 h, pulsed with 10
µM EdU for 30min and, after washing, incubated in fresh medium containing 5 µM thymidine for 2, 4, 6, 8 and 10 h. After a second pulse of 30min with 10
µM, BrdU cells were fixed for immunofluorescence. d EdU/BrdU double staining of siSC and siEnsa-treated cells at 10 h after thymidine release is shown.
EdU-positive cells are labelled in magenta and BrdU-positive cells in cyan. Resulting white co-localisation are cells still in S phase. Scale bar, 20 μm. e The %
of EdU/BrdU-positive cells in d was counted and represented as a bar graph of the mean value ± standard deviation. A minimum of 80 cells was counted in
each time point. f HeLa cells were or not (CT) transfected with increasing doses of siEnsa (12.5, 25 and 50 nM) and 24 h later synchronised in S phase by
thymidine block. Cells were then released and followed by time-lapse microscopy. Time after thymidine release and cell rounding (G2/M transition) for
each cell at each siRNA concentration was recorded and represented as a box-and-whiskers diagram showing median and minimum to maximum values. A
minimum of 50 cells was counted per condition. g Asynchronous control or HeLa cells stably expressing a siEnsa-resistant transgene of human Ensa (R-
Ensa) were transfected with siEnsa1 or with SC siRNA (only for parental cells). Cells were released 24 h later, recovered and used for FACS analysis. h As
for g, except that cells were blocked in G1–S 24 h after transfection by thymidine and 9 h after release used for FACs analysis
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siEnsa-treated cells, these factories were dramatically bigger.
Moreover, the nucleoli were hardly visualised in siEnsa-treated
cells, with PCNA staining no longer continuously surrounding
nucleoli, but rather displaying discrete, pointed localisation
(Fig. 4c, Supplementary Movies 1–6).
We next measured the time after thymidine release when each
type of factory was visualised. Our quantification data
demonstrate that the general spatiotemporal patterns of replica-
tion foci were not perturbed with all (early, mid and late S phases)
patterns being extended proportionally (Fig. 4d, Table 1,
Supplementary Fig. 2a and Supplementary Movies 1–6). Similar
results were obtained when the time between early–mid–late
phase transitions were measured by using double EdU/BrdU
staining and immunofluorescence (Supplementary Fig. 2b, c).
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These data indicate that S-phase delay is likely due to a general
inhibition of the firing of all, early, mid and late origins,
suggesting that this delay could stem from a general defect in
DNA replication initiation factor(s).
The knockout of Gwl also promotes partial S-phase extension.
We next checked the effect of the depletion of Gwl on S-phase
length. To do this, we used Gwl(Lox/Lox) or control mouse
embryonic fibroblasts (MEFs)17 in which Gwl ablation is induced
by the transduction of GFP-Cre-expressing adenoviruses
(Fig. 5a). We did not observe any effect when control MEFs were
infected with the plasmid coding for GFP-Cre (Fig. 5b) or when
Gwl(Lox/Lox) MEFs were infected with the GFP-expressing
adenoviruses (Fig. 5c). As shown previously, the acute expression
of GFP-Cre in asynchronous Gwl(Lox/Lox) MEFs promoted an
accumulation of mitotic cells and cells with 8n DNA content due
to the lack of chromosome segregation and/or to cytokinesis
defects17, 18 (Fig. 5d). However, we also observed a partial
accumulation of cells in S phase. To further investigate this
phenotype, MEF Gwl(Lox/Lox) cells were serum-starved for
3 days and subsequently infected with GFP as a control (Fig. 5e)
or GFP-Cre-expressing adenoviruses (Fig. 5f). Five hours later,
cells were supplemented with fresh medium containing aphidi-
colin for 24 h and were recovered for FACS analysis at 5 and 14 h
after release. As expected, both control and Gwl-ablated MEFs
were in S phase at 5 h after release, however, at 14 h, control cells
were out of S phase, whereas Gwl knockout cells significantly
accumulated at this phase of the cell cycle. To quantify this S
phase accumulation, we synchronised infected control (GFP) and
knockout (GFP-Cre) MEFs by the addition of aphidicolin for 24 h
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determine the statistical relevance ***p< 0.0001. Data pooled from three biological replicates. b Representative images of early, mid and late replication
factories from HeLa chromobody control cells used for time-lapse microscopy. Scale bar, 10 μm. c Representative images of mid-replication origins from
Supplementary Movies 1–6. Images corresponding to three Z-planes of three scramble and three siEnsa-treated HeLa cells stably expressing a chromobody
directed to PCNA. Plans correspond to 4 h, 3 h 20min and 4 h 15 min time points after DNA replication started in siSC-treated cells 1, 2 and 3 and to 5 h 15
min, 5 h 15 min and 6 h 50min time points in siEnsa-treated cells 1, 2 and 3 from movies on supplementary data. Scale bar, 10 μm. d HeLa chromobody cells
treated as in c were imaged by time-lapse microscopy and the length of the early, mid and late S-phase patterns was recorded and represented as a bar graph
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and we performed a pulse of 30 min of BrdU at different times
post release. Cells were then fixed and immunostained with anti-
BrdU antibodies. The number of S-phase cells in control and Gwl
knockout cells were then counted at each time point and com-
pared. As shown in Fig. 5g, in control MEFs, BrdU incorporation
peaked at 6 h, decreasing slightly till 10 h before significantly
decreasing from 13 to 18 h, indicating that S-phase length was
~10 h. In contrast, in Gwl knockout MEFs, high BrdU staining
was maintained until 15 h after release and did not start to
decrease until 18 h, suggesting that S phase was also partially
extended by Gwl knockout in these cells.
Active Gwl and Ensa are localised in the nucleus in S phase.
The above results suggest that Gwl, likely by phosphorylating
Ensa, participates to the control of S phase. We therefore checked
the localisation of both Ensa and Gwl during S phase. Previous
reports17, 18 showed that Gwl was localised in both nuclei and
cytoplasm, however, whether this nuclear localisation is observed
during S phase or the other phases of the cell cycle is not known.
We checked nuclear localisation of Gwl by immunofluorescence
in BrdU-labelled cells. As shown in Fig. 6a, nuclear localisation of
Gwl was constant throughout interphase and no differences were
observed when BrdU-positive and -negative cells were compared.
In contrast, nuclear localisation of Ensa was significantly
increased in S-phase cells suggesting that Ensa is relocalised into
the nucleus during DNA replication.
Nuclear localisation of Ensa in S phase is compatible with a
role of this protein in DNA replication. We thus further
investigated if Ensa was phosphorylated and activated during S
phase by Gwl. To that, we checked Ensa phosphorylation in Ensa
immunoprecipitates of HeLa cells during the different phases of
the cell cycle by using a phospho-antibody that recognises the
conserved phosphorylated site of Gwl in both human Arpp19
(S62) and human Ensa (S67). Phosphorylation of Ensa by Gwl
significantly increased in S phase compared to G1/S but to a lower
extent than in mitosis (Fig. 6b). We next checked the levels of
active Gwl on the chromatin during S phase. Hence, thymidine-
blocked HeLa cells were lysed to recover cytoplasm and nuclei at
2, 4, 6 and 8 h after release. Chromatin-associated proteins were
then extracted by using a buffer containing 300 mM (N3) or 600
mM of NaCl (N6). As shown in Fig. 6c, Gwl was present and
bound to the chromatin throughout S phase although to a lesser
extent than in cytoplasmic fraction. Moreover, phosphorylation
and activation of Gwl was observed in nuclear but not in
cytoplasmic fractions of thymidine-blocked cells. Gwl phosphor-
ylation in nuclear fractions was maintained 2 and 4 h after release,
decreased at 6 h and disappeared at 8 h when S phase is
completed. These results indicate that Gwl and Ensa are present
and active on the chromatin during S phase.
Ensa KD lowers Treslin protein levels. It is known that the Gwl/
Ensa pathway regulates mitotic entry and progression by pro-
moting the inhibition of PP2A-B55, the phosphatase responsible
of cyclin-Cdk substrate dephosphoryaltion19, 24. We investigated
the effect of Ensa KD on the global phosphorylation of Cdk
substrates by using an antibody directed against the phosphory-
lated serine in the Cdk consensus motif. As shown in Fig. 7a, b,
we observed a significant decrease of the phosphorylation of
cyclin-Cdk substrates in Ensa KD cells. We hypothesised that the
Gwl/Ensa pathway might be activated in S phase to permit the
phosphorylation of key Cdk substrates responsible for the correct
unfolding of S phase. One major Cdk substrate whose phos-
phorylation controls S-phase length is the TopBP1-interacting
protein, Treslin14. We therefore checked whether Treslin was
dephosphorylated upon Ensa KD. To our surprise, the main
phenotype that we observed after siEnsa treatment was a dra-
matic drop of this protein in both HeLa and in U2OS cells (Fig. c
and d) and in U2OS cells overexpressing Treslin (Fig. 7e, f). This
decrease was not due to a decline of the mRNA transcripts of this
protein (Fig. 7g). We observed a similar drop of Treslin levels in
Gwl knockout MEF cells supporting the hypothesis that the role
of Ensa in S phase is mediated by the Gwl-dependent phos-
phorylation of this protein (Fig. 7h, i). Since no data about a
putative control of Treslin amount during cell division were
reported, we checked endogenous Treslin levels throughout the
cell cycle. Our data show that the endogenous levels of this
protein are high during M/G1, drop during S phase and increase
again in G2 to reach maximum levels at M phase suggesting that
Treslin levels would be tightly controlled during DNA replication
(Supplementary Fig. 3). Interestingly, although endogenous Tre-
slin was high during mitosis, a decrease of this protein after Ensa
KD was also observed during mitosis indicating that the Ensa-
dependent Treslin stabilisation pathway is also active during this
phase of the cell cycle (Fig. 7j, k).
Treslin rescues S-phase length in Ensa KD cells. The above data
show that Ensa KD induces a dramatic decrease of Treslin levels.
Lower Treslin levels might decrease the number of fired repli-
cation origins, and consequently lead to a longer S phase. If this
was the case, recovering normal Treslin levels should rescue the
Ensa KD phenotype. We therefore tested whether Treslin over-
expression restores S-phase length in Ensa knocked down cells.
Ensa was knocked down by siRNA in a U2OS cell line stably
overexpressing Treslin (Fig. 8a), and Treslin levels (Fig. 8b, c)
along with S-phase duration was measured by FACS at 7.5 and
10 h post-thymidine release (Fig. 8d, e, respectively). As shown in
Fig. 8a, Ensa was efficiently knocked down in both parental and
Treslin-overexpressing UO2S cells. The Treslin-U2OS stable cell
line (CT) expressed approximately four times more Treslin than
scramble treated U2OS cells (compare CT in Treslin-U2OS cells
with sSC in U2OS cells in Fig. 8c). As expected, we saw a decrease
of Treslin amounts in U2OS control cells after Ensa KD (compare
siSC vs siE1 and siE2 in U2OS cells in Fig. 8b, c). Treslin levels
also decreased in the Treslin-U2OS stable cell line depleted of
Ensa, however the levels of this protein remained above endo-
genous siSC-treated controls (Fig. 8c, compare siSC vs siE1 and
siE2 in Treslin-U2OS cells). Importantly, FACS data analyses
showed that S-phase progression is as fast after Ensa KD in U2OS
cells overexpressing Treslin than in normal U2OS cells treated
with scramble siRNA. In contrast, in U2OS cells treated with
siEnsa1 or 2, S phase was extended as before. These data support
the idea that the S-phase extension caused by Ensa KD stems
from the decrease of Treslin protein levels, which is one of the
limiting factors regulating the firing of replication origins and
controlling replication timing.
Table 1 Spatiotemporal patterns of replication of Ensa KD
cells
Early Mid Late
siSC siEnsa siSC siEnsa siSC siEnsa
Mean time (min) 128.5 192.75 170 261 151.6 305
Standard
deviation
40.7 80.2 40.8 100.9 67.01 89.8
n (cells) 18 20 18 20 18 20
p-value (t-test) 0.0039 0.0012 0.0021
Length of the early, mid and late S-phase patterns were counted in cells from Fig. 4. Mean,
standard deviation, number of cells and p-value obtained by using two-tailed unpaired Student’s
t-tests between siSC and siEnsa treatments are represented in the table. Data correspond to
three different experiments
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Ensa stabilises Treslin by preventing its dephosphorylation.
The findings above suggest that Ensa depletion either reduces
Treslin translation or promotes Treslin degradation. No data
about a putative regulation of Treslin protein levels have ever
been reported. Thus, we used the proteasome inhibitor MG132 to
check whether Treslin is degraded by the proteasome. No major
effects in cell cycle progression were observed after MG132
addition in HeLa cells (Supplementary Fig. 4a). As previously
reported25, the addition of this proteasome inhibitor promoted a
small increase of S-phase cells that was identical in all parental,
siSC and siEnsa-treated U2OS cells and that in the latter, accu-
mulated with the S-phase delay already present in non-treated
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Fig. 5 The knockout of Greatwall, the upstream kinase of Ensa, also results in partial S-phase accumulation. a Control or MEF Gwl(Lox/Lox) cells were
serum-starved for 3 days, infected for 5 h with GFP or GFP-Cre-expressing adenoviruses as indicated, stimulated to re-enter the cell cycle with fresh
serum-supplemented media and recovered for western blot with the indicated antibodies. b FACS analysis 48 h after infection in control MEFs infected
with GFP-Cre adenoviruses. c GwlLox/Lox MEFs infected with control GFP adenovirus. d GwlLox/Lox MEFs infected with GFP-Cre adenovirus. e MEF
GwlLox/Lox cells were serum-starved for 3 days and subsequently infected with GFP-expressing adenovirus. Five hours later, cells were supplemented with
fresh medium containing aphidicolin for 24 h. S-phase synchronised cells were then released and recovered at 5 and 14 h for FACS analysis. f As for e,
except that GFP-Cre-expressing adenoviruses was used. g S-phase synchronised cells infected with GFP (control) and GFP-Cre (Gwl knockout)
adenoviruses as in e and f were released and a pulse of 30min of BrdU at the indicated time points was performed. Cells were then fixed and
immunostained with anti-BrdU antibodies. The number of S-phase cells in control and Gwl knockout cells were counted at each time point, compared and
represented as a bar graph of the mean value of three different samples ± standard deviation. A cell number between 175 and 565 were counted for each
time point
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Ensa KD cells (Supplementary Fig. 4b). Treslin significantly
accumulated after MG132 addition in both HeLa (Fig. 9a) and
U2OS cells (Fig. 9b). A comparable accumulation was observed in
Ensa knocked down cells although, as expected, in this case
Treslin basal levels were significantly lower than in control cells.
Treslin levels also increased when the activity of the Cullin-
dependent E3 ubiquitin ligases were blocked in both scramble
and Ensa siRNA-treated cells by using the NEDDylation acti-
vating enzyme inhibitor, MLN4924 (Fig. 9a, b). These results
indicate that Treslin is an unstable protein that is likely degraded
by Cullin-proteasome pathway. Since Treslin accumulated in
both control and Ensa knocked down cells, these data also suggest
that Ensa depletion does not prevent Treslin translation but
rather promotes a drop of Treslin levels by increasing the
degradation of this protein. Accordingly, Treslin levels also dra-
matically decreased in U2OS cells stably overexpressing Treslin
(Treslin-U2OS) when treated with siEnsa. Moreover, the addition
of MG132 to these cells promoted the accumulation of Treslin
(Fig. 9c).
The binding of certain Cullins, notably of the Cul1-CRL
complex (SCF) to their substrates is mediated by phosphoryla-
tion. It is known that Treslin is phosphorylated by Cdk at S phase.
We thus tested whether Cdk-dependent phosphorylation of
Treslin could regulate the proteolysis of this protein. To that, we
checked the degradation pattern of ectopic wild type or of a
phosphomimetic Treslin mutant on the T968 and S1000 Cdk sites
(TESE mutant) in HeLa and U2OS cells (Fig. 9d, e, respectively).
These cells were supplemented with cycloheximide to prevent
vector promoter-induced continuous synthesis of the ectopic
Treslin. No effect of cycloheximide addition in cell cycle
progression was observed (Supplementary Fig. 5). As expected,
wild-type Treslin levels drop in both cell lines when protein
synthesis was inhibited by the addition of cycloheximide. On the
contrary, the phosphomimetic TESE mutant was stable through-
out the experiment under these conditions suggesting that the
phosphorylation of Treslin by Cdk stabilises this protein. Similar
results were obtained in siEnsa-treated cells (Fig. 9f). Since the
Gwl/Ensa pathway controls the phosphorylation of Cdk sub-
strates by inhibiting PP2A, we next tested whether Ensa KD could
promote Treslin degradation by inducing the PP2A-dependent
dephosphorylation of this protein. HeLa and U2OS cells were
transfected with scramble or Ensa siRNAs and 24 h later,
supplemented with a low dose of the PP2A inhibitor okadaic
acid (5 nM) for a supplementary 24 h incubation. The cellular
levels of Treslin were then measured by western blot (Fig. 9g, h,
respectively) and cell cycle distribution in treated HeLa cells
analysed by FACs (Fig. 9i). Scramble-treated cells displayed a
normal FACs profile and identical Treslin levels indistinctly of the
presence or absence of okadaic acid. Conversely, as expected,
Ensa knocked down cells accumulated in S phase and displayed a
drop of Treslin in the absence of okadaic acid, a phenotype that
was significantly rescued when the PP2A inhibitor was supple-
mented. These data suggest that Ensa, via PP2A inhibition,
controls Treslin stability by modulating Cdk-dependent phos-
phorylation of this protein.
Discussion
The Gwl/Arpp19-Ensa/PP2A-B55 axis was originally identified in
Xenopus egg extracts26–28 and subsequently reported in other
models such as Drosophila29 and human cells17, 18. Activation of
the Gwl kinase induces the phosphorylation of Ensa, promoting
their binding to and inhibition of the phosphatase
PP2A-B5519, 20. Inhibition of PP2A-B55 results in the stable
phosphorylation of cyclin B-Cdk1 substrates and mitotic entry.
So far, the activation of this pathway has been reported in
mitotic cells, however, it has been recently demonstrated that Gwl
has additional roles and is involved in regulating Akt activation
pathway30. This raises the possibility that the Gwl-Ensa-PP2A
pathway is functional outside of mitosis. To test this, we inves-
tigated the role of Ensa in human cells using siRNA KD. Unex-
pectedly, the first phenotype that was observed in knocked down
cells was a dramatic extension of S phase. This extension was
displayed in both HeLa and U2OS cells and was specific to Ensa
depletion, since the same siRNA treatment in a cell line stably
expressing a siRNA-resistant Ensa transgene completely rescued
the phenotype. Interestingly, S-phase delay induced by Ensa KD
was mediated by a decrease of the number of fired replication
origins without affecting either origin licensing or fork velocity. In
addition, the ‘in vivo’ analysis of replication factory dynamics in
Ensa KD cells using a anti-PCNA GFP chromobody-expressing
cell line revealed that the general spatiotemporal pattern of early,
mid and late replication factories was not altered during S phase,
despite a clear extension of the time each of these patterns lasted.
Together, these data indicate that the spatiotemporal extension is
likely induced by a general decrease of the firing of early, mid and
late replication origins resulting in an increase of S-phase
duration.
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Interestingly, our data also reveal that this general decrease of
early, mid and late origin firing in Ensa knocked down cells is the
result of a dramatic drop of Treslin levels, which is an essential
and limiting factor for origin firing12, 14, 31. Consistently, we show
that the S-phase extension is suppressed when the original Treslin
levels are recovered by ectopic expression despite Ensa KD.
Another key result of our study highlights the fact that Treslin
is a highly unstable protein whose levels are likely regulated by
Cullin-dependent ubiquitination and proteasome degradation. In
addition, our data suggest that depletion of Ensa promotes an
increase of Treslin ubiquitin/proteasome-dependent degradation
in both U2OS and HeLa cells. This hypothesis is supported by the
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represented as a bar graph ± standard deviation. e U2OS cells overexpressing Treslin were treated with scramble (siSC) or Ensa siRNA and used for
western blot. f Mean Treslin/Vinculin ratios were normalised to controls and represented as a bar graph ± standard deviation. g Treslin mRNA levels
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fact that the addition to Ensa knocked down cells of either the
proteasome inhibitor MG132 or of the NEDDylation activating
enzyme inhibitor, MLN4924 prevents the drop of Treslin levels.
Interestingly, our findings indicate that the phosphorylation of
Treslin by Cdk stabilises this protein, whereas its depho-
sphorylation by PP2A promotes its proteolysis, suggesting that
the Gwl/Ensa pathway controls S-phase length by modulating the
PP2A-dependent dephosphorylation and degradation of Treslin.
We do not know which is the physiological function of Treslin
instability, however, taking into account the essential role of this
protein in replication origin firing, we could hypothesise that its
quick degradation in response to massive replicative stress could
rapidly and efficiently delay S-phase progression in response to
the intra S-phase checkpoint activation. In addition, the regula-
tion of the levels of this protein could similarly contribute to the
establishment of the diverse replication timing programs dis-
played in different cell types or in differentiated cells25.
In summary, here we identify a new regulatory mechanism
controlling S phase that involves the regulation of Treslin levels
by the Gwl/Ensa pathway via the control of the PP2A-dependent
dephosphorylation and Cullin-dependent degradation of this
protein. This mechanism is essential to modulate replication
timing under physiological conditions. Further studies will be
required to determine whether this pathway could also participate
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to the intra-S-phase checkpoint response under pathological
conditions.
Methods
Cell lines, transfection, infection and synchronisation. HeLa and U20S cells
were obtained from ATCC collection. HeLa PCNA chromobody cells were pur-
chased from Chromotek22 and U20S cells stably expressing AcGFP-Flag-Treslin
were a generous gift of Dr J.F.X. Diffley31. All these cells were cultured in DMEM
media supplemented with 10% foetal bovine serum. Stable HeLa cells were gen-
erated using PMX-puro Human Ensa modified to be resistant to siRNA Ensa1
using site-directed mutagenesis with the oligonucleotide 5′-AACATGGC-
CAAAGCTAAAATGAAGAACAAACAGCTGCCAAGT-3′ (bold letters corre-
spond to the four mutated nucleotides). Phosphomimetic Treslin T968E S1000E
mutant were created from pcDNA5 TO human WT Treslin 3xFlag (gift from W.G.
Dunphy) using the Quick change kit (Agilent Technologies) and all mutations were
confirmed by DNA sequencing. Oligonucleotides used for site-directed mutagen-
esis were purchased from Eurogentec (T968E: 5′-
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cells stably expressing Treslin cDNA were transfected with siSC or siEnsa and subsequently incubated with (2 h) or without (−) MG132 (10 µM) and
Treslin amount checked by western blot. d HeLa cells overexpressing a Flag-tagged wild-type (WT) Treslin or the phosphomimetic mutant of this protein
T968E/S1000E (TESE) were incubated with cycloheximide for the indicated periods of time and submitted to western blot to measure ectopic Treslin
levels. e As for d, except that U2OS instead of HeLa cells were used. f HeLa and U2OS cells were co-transfected with Flag-tagged wild type or the T968/
S1000E Treslin mutant and treated with siSC or siEnsa and used for western blot to measure ectopic Treslin levels g HeLa cells were transfected with
scramble (siSC) and Ensa (siEnsa) siRNAs and 24 h later incubated (+) or not (−) with the PP2A inhibitor okadaic acid (OA; 5 nM). Cells were recovered
24 h later and used for western blot. h As for g, except that U2OS instead of HeLa cells were used. i FACs analysis for HeLa cells in g is shown
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ACTAAGAGTGTGGCCGAGGAACCAGTGCATAAGCAGATC-3′ and S1000E:
5′-ATTGGTGTTGTTGAAGAGGAACCTGAAAAAGGAGATGAAA-3′) (bold
letters correspond to the mutated oligonucleotides).
For synchronisation experiments, cells were arrested in G1/S with 2.5 mM
thymidine for 24 h. Cells were then washed three times with pre-warmed media,
and released from G1/S arrest by adding fresh media. To block cells at the G2/M
transition, cells were incubated with 10 µM RO-3306 (Tocris Bioscience). Mitotic
cells were obtained by shakeoff after nocodazole treatment (100 ng/ml for 16 h).
Gwl(Lox/Lox) MEFs were grown as described in Alvarez-Fernandez et al.17 For
knockout induction, MEF cells were deprived of serum for 72 h, subsequently
transduced with AdenoGFP or AdenoGFP-Cre viruses (gene transfer core vector;
University of Iowa, USA) during 5 h and finally stimulated to re-enter the cell cycle
with fresh serum-supplemented media. G1/S synchronisation was induced in these
cells by aphidicolin (2 µg/ml) for 24 h.
HeLa or U2OS cells were treated with the proteasome inhibitor 10 µM of MG132
for 2, 4 or 6 h (Tocris), or with the NEDDylation activating enzyme inhibitor,
MLN4924 (500 nM for 8 h) (Active Biochemicals Co.), with 5 nM of okadaic acid
for 24 h, or with cycloheximide (CHX, Sigma) at 40 µg/ml for 2, 4, 6 or 8 h.
siRNAs were synthetised using T7 RiboMaX TM Express RNAi system
(Promega) and were transfected with Lipofectamine RNAimax (Life Technologies)
according the manufacturer’s instructions at a concentration of 50 nM. Double
transfection of siRNA and the wild-type or the mutant form of Treslin were
performed using Lipofectamine 2000 (Life Technologies) in cells in suspension.
siRNA SC (scramble): 5′-CTTAGCTACGATCAAGTAC-3′
siRNA Ensa #1: 5′-GCCAAGATGAAGAATAAGC-3′ (271–289)
siRNA Ensa #2: 5′-GAAACAAGAAGAAGAGAAC-3′ (9–27).
Fluorescence-activated cell scanning. For FACS, cells were fixed with ice-cold
70% ethanol at −20 °C, and washed with phosphate-buffered saline (PBS), DNA
was stained with a solution containing propidium iodide (5 µg/ml) and RNAse A
(0.5 mg/ml) in PBS. For bivariate FACS analysis, cells were pre-labelled with 10 μM
BrdU (Sigma) for 30 min, harvested via trypsinisation and fixed as describe above.
Fixed cells were washed once with PBS and incubated with 2M HCl, 0.5% (vol/vol)
Triton X-100 for 30 min, with gentle mixing. After two washes in PBS, cells were
incubated 2 h at room temperature with anti-BrdU antibody (Santa Cruz Bio-
technology Inc.) and diluted 1/30 in PBS containing 1% BSA, 0.5% Tween 20.
Then, BrdU staining was revealed with Alexa Fluor 488-conjugated goat anti-
mouse antibody and DNA with a 7AAD (1.5 µg/ml) and RNAse A (0.5 mg/ml) in
PBS. Finally, cells were analysed on a FACS Calibur (BD Biosciences) using Cell
Quest Pro and Flow Jo software.
DNA combing. DNA combing was performed as described in Bialic et al.32 Briefly,
cells were pulsed with IdU (25 µM) for 15 min, then with CldU (200 µM) for 15
min, before proceeding to a thymidine (1 mM) chase for 2 h. After trypsinisation
and cell counting, 50,000 cells were resuspended in PBS, pre-warmed at 42 °C, then
mixed with an equal volume of 1% low-melting agarose. Agarose plugs were treated
overnight at 37 °C with 0.2 mg/ml proteinase K before melting with ß-agarase,
DNA combing and signal detection with antibodies against ssDNA (Millipore
MAB3034, 1/300), IdU (Becton-Dickinson clone B44, 1:20) and CldU (AbCys
clone Bu 1/75) along with appropriate fluorescently labelled secondary antibodies.
After image acquisition, fork velocities were calculated on bicolour ongoing forks
away from the fibre edge by dividing the length of the second (CldU) tract by the
duration of the second pulse (15 min) using 2 kb/µm as stretching rate. Fork
density was calculated by dividing the total number of ongoing forks with the total
length of DNA fibres, after correction for the percentage of cells in S phase32.
Cell extracts and chromatin isolation. Cells cultured in 35, 60 or 100 mm dishes
were rinsed in cold PBS and lysed in 50 mM Tris-HCl, pH 7.5, 120 mM NaCl, 20
mM NaF, 1 mM EDTA, 6 mM EGTA, 15 mM NaPPi, 15 mM pNPP, 1 mM ben-
zamidine, protease inhibitor cocktail, 0.5 mM vanadate, and 1% Nonidet P-40 or in
Laemmli buffer (Tris-HCl 10 µM, pH 6.8, SDS 1%, glycerol 5%, β-mercaptoethanol
0.5%, DTT 1 µM) before sonication (30 s). To isolate chromatin, cells were
resuspended (4x107 cells per ml) in buffer A (10 mM HEPES—pH 7.9, 10 mM KCl,
1.5 mM MgCl2, 0.34 M sucrose, 10% glycerol, 1 mM DTT, 1× protease inhibitor
cocktail) and processed as described by Méndez and Stillman33. Briefly, 0.1% of
Triton X-100 was added and cells were incubated 1 min on ice before cen-
trifugation at 1300 × g for 5 min. The supernatant (S1) is then clarified by high-
speed centrifugation (10 min, 20,000 × g, 4 °C) to remove cell debris and insoluble
aggregates. The new supernatant (S2) contains soluble cytoplasmic proteins. Nuclei
were collected in pellet 1 (P1) by low-speed centrifugation (5 min, 1300 × g, 4 °C)
after a wash in buffer A without Triton X-100, and were lysed for 30 min on ice in
buffer B (3 mM EDTA, 0.2 mM EGTA, 1 mM DTT and 1× protease inhibitor
cocktail). Insoluble and chromatin enriched fraction (P3) was collected by cen-
trifugation (5 min, 1700 × g, 4 °C), washed once in buffer B and centrifuged again
under the same conditions. The final chromatin pellet was resuspended in Laemmli
sample buffer and sonicated for 20 s. The first supernatant (S3) contains soluble
nuclear fraction.
Antibodies and immunoblots. Proteins (20–50 µg) were loaded on a poly-
acrylamide gel and then transferred onto Immobilon-P. Membranes were incu-
bated with homemade rabbit polyclonal antibodies raised against recombinant full
length 6His-human Ensa protein (anti-hEnsa) (1/1000), phospho-Arpp19/Ensa
S67/S71 (Cell Signaling, #5240, 1/250,), human Greatwall (anti-hGreatwall) (1/
1000), phospho-Greatwall S87534, α-Tubulin (1/1000 clone C102, generous gift of
J.M. Andreu, Spain), Treslin (1/1000, Bethyl Laboratories Inc., A303-472A),
phospho-Ser CDK substrate (1/1000, Cell Signalling, #9477S), Histone H3 (1/500,
Santa Cruz, Biotechnology Inc., SC-FL136), Cdk1 (1/1000, Santa Cruz, Bio-
technology Inc., SC-954), MCM-2 (1/10000, Abcam, ab4461), MCM-3 (1/2500,
Abcam, ab4460), MCM-4 (1/5000, Abcam, ab4459) and MCM-5 (1/5000, Abcam,
ab17967). Mouse monoclonal used are MCM-7 antibody (1/1000, Abcam, ab2360),
Flag M2 (1/500, Sigma, F3165), Vinculin (1/1000, Sigma,V9131 Hvin-1) and
β-Tubulin (1/500, clone E7, generous gift from N. Morin). Uncropped scans of all
the western blot membranes are supplied in the Supplementary Information file.
Immunoprecipitation. Cells were lysed in NETN buffer (0.25% IGEPAL, 150 mM
NaCl, 50 mM Tris and 1 mM EDTA) complemented with 500 nM microcystin-LR.
Immunoprecipitations were carried out for 1 h at room temperature using 400 µg
of protein and 2 µg of Ensa polyclonal antibody affinity purified against 6His-
human Ensa protein immobilised on protein A (Dynal Beads, Invitrogen).
Immunoprecipitates were then analysed by immunoblotting as described above.
EdU/BrdU labelling. Cells were grown on glass coverslips and pulsed with 10 µM
EdU and/or 10 µM BrdU for 30 min. For EdU/BrdU kinetics, cells were grown in
media containing 5 µM thymidine between the two stainings. Cells were then fixed
for 15 min in PBS with 3.2% formaldehyde and permeabilised in 0.2% Triton X-100
for 10 min, then treated with 4 N HCl for 20 min. All cells were washed and
blocked (3% BSA, 0.1% Tween 20 in PBS) for 45 min. Click-iT- EdU Alexa
530 staining was performed as per manufacturer instruction (Invitrogen). After
three washes in PBS, cells were incubated with monoclonal anti-BrdU antibody
(1/400, MoBu-1 Exbio, #11-286-100), and revealed by an Alexa Fluor 633 con-
jugated goat anti-mouse antibody. Coverslips were mounted using Prolong Gold
mounting medium (Invitrogen) and captured using a confocal Leica SP5-SMD
microscope, with a Leica ×63/APO 1.4 lens, powered by LASAF software. Serial 0.5
µm Z-sections were taken, and maximum projections were generated by using
Image J software.
Immunohistochemistry. Cells were fixed as above, permeabilised in 0.2% Triton
X-100 and incubated with rabbit polyclonal anti-hEnsa (1/100), anti-hGreatwall
(1/100) and monoclonal anti-BrDU. Antibodies were revealed with anti-Rabbit
Alexa Fluor 546 (Life Technologies, A11035, 1/1000), anti-Mouse Alexa Fluor 546
(Life Technologies, A11018, 1/1000), anti-Rabbit Alexa Fluor 488 (Life Technol-
ogies, A11070, 1/1000) and anti-Mouse Alexa Fluor 488 (Life Technologies,
A11017, 1/1000).
Alexa Fluor 546-conjugated or Alexa Fluor 488-conjugated goat anti-rabbit or
mouse antibodies (Molecular Probes, Life Technologies). Cells were analysed as
described previously35. Images were taken with a Leica SP5 confocal microscope or
with a MetaMorph-driven software (Molecular Devices, Sunnyvale, CA) wide-field
Axioimager Z2 fluorescence microscope (Zeiss, Jena, Germany) with a PL APO
×63 or ×40 objectives (numerical aperture 1.32; Leica, Melville, NY) and a
CoolSNAP HQ2 3 camera (Photometrics, Woburn, MA). For quantification
experiments, cells were acquired using scan slide module and analysed with ImageJ.
Images were then processed using Photoshop (Adobe, San Jose, CA).
Live imaging. HeLa PCNA chromobody cells (Chromotek)22 were transfected with
SC siRNA or Ensa siRNA during 24 h, then blocked in G1/S with thymidine for 24
h, and released in fresh medium before analysis by time-lapse microscopy. Time-
lapse confocal microscopy was performed using a spinning disk CSU-X1 Andor
coupled to an NIKON inverted microscope. Images were acquired with 20 Z-
section at 0.7 µm steps, taken every 5 min for up to 72 h with a ×40/1.6 lens.
Maximum projections were generated using Image J.
RT-PCR and real-time quantitative PCR. RNAs from cell lines were isolated
using the RNeasy Mini kit (Qiagen). Five micrograms of total RNA was reverse
transcribed using oligodT (Roche) in a final volume of 20 µl using Superscript III
(Invitrogen). After reverse transcription, 100 ng of cDNA was used for real-time
quantitative PCR, performed with a Lightcycler and the SYBR Green fast start kit
(Roche, Germany). Primers sequences used in real-time PCR specific for human
TICRR (Treslin) genes as well as for the housekeeping gene MRPL19 were as
follows:
HumTreslin-F: 5′-AAACACTTTGGATTCGGAGGT-3′;
HumTreslin-R 5′- TTCTGCAGCCTTTCTGGAGT-3′;
HumMRPL19-F: 5′-GGGATTTGCATTCAGAGATCAG-3′;
HumMRPL19-R: 5′-GGAAGGGCATCTCGTAAG-3′.
Data availability. The data that support the findings of this study are available
form the corresponding author upon reasonable request.
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